Cardiopulmonary assessment of patients diagnosed with Gaucher’s disease type I

por Bjelobrk, Marija, Lakocevic, Milan, Damjanovic, Svetozar, Petakov, Milan, Petrovic, Milan, Bosnic, Zoran, Arena, Ross, Popovic, Dejana
Publicado 2021

Peripheral neural response and sex hormones in type 1 Gaucher disease

por Lakočević, Milan B., Platiša, Mirjana M., Šumarac, Zorica R., Suvajdžić, Nada D., Mačukanović, Lana Đ., Petakov, Milan S.
Publicado 2020

Immunoglobulin Heavy Chain Gene Rearrangements in Patients with Gaucher Disease

por Rodić, Predrag, Lakočević, Milan, Pavlović, Sonja, Đurašević, Teodora Karan, Kostić, Tatjana, Vuković, Nada Suvajdžić, Šumarac, Zorica, Petakov, Milan, Janić, Dragana
Publicado 2018

Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion

por Stojanovic, Marko, Wu, Zida, Stiles, Craig E, Miljic, Dragana, Soldatovic, Ivan, Pekic, Sandra, Doknic, Mirjana, Petakov, Milan, Popovic, Vera, Strasburger, Christian, Korbonits, Márta
Publicado 2019

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

por Pastores, Gregory M., Shankar, Suma P., Petakov, Milan, Giraldo, Pilar, Rosenbaum, Hanna, Amato, Dominick J., Szer, Jeffrey, Chertkoff, Raul, Brill‐Almon, Einat, Zimran, Ari
Publicado 2016

The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors

por Ognjanović, Sanja, Macut, Djuro, Petakov, Milan, Elezović Kovačević, Valentina, Isailović, Tatjana, Bozić Antić, Ivana, Ilić, Dušan, Popović, Bojana, Bogavac, Tamara, Pekmezović, Tatjana, Damjanović, Svetozar
Publicado 2016

Novel Mutations in Serbian MEN1 Patients: Genotype-phenotype Correlation

por Isailovic, Tatjana, Milicevic, Ivana, Macut, Djuro, Petakov, Milan, Ognjanovic, Sanja, Popovic, Bojana, Antic, Ivana Bozic, Bogavac, Tamara, Kovacevic, Valentina Elezovic, Ilic, Dusan, Damjanovic, Svetozar
Publicado 2019

MON-LB56 Metabolic Profile in 107 Patients With Childhood Onset Growth Hormone Deficiency (CO-GHD) at the Time of Transition From Pediatric to Adulthood Endocrine Care

por Doknic, Mirjana, Stojanovic, Marko, Milenkovic, Tatjana, Zdravkovic, Vera, Jesic, Maja, Todorovic, Sladjana, Mitrovic, Katarina, Vukovic, Rade, Miljic, Dragana, Pekic, Sandra, Soldatovic, Ivan, Petakov, Milan
Publicado 2020

The cognitive profile of type 1 Gaucher disease patients

por Biegstraaten, Marieke, Wesnes, Keith A., Luzy, Cécile, Petakov, Milan, Mrsic, Mirando, Niederau, Claus, Giraldo, Pilar, Hughes, Derralynn, Mehta, Atul, Mengel, Karl-Eugen, Hollak, Carla E. M, Maródi, László, van Schaik, Ivo N.
Publicado 2012

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

por Zimran, Ari, Durán, Gloria, Mehta, Atul, Giraldo, Pilar, Rosenbaum, Hanna, Giona, Fiorina, Amato, Dominick J., Petakov, Milan, Muñoz, Eduardo Terreros, Solorio‐Meza, Sergio Eduardo, Cooper, Peter A., Varughese, Sheeba, Chertkoff, Raul, Brill‐Almon, Einat
Publicado 2016

Mapping the journey of transition: a single-center study of 170 childhood-onset GH deficiency patients

por Doknic, Mirjana, Stojanovic, Marko, Soldatovic, Ivan, Milenkovic, Tatjana, Zdravkovic, Vera, Jesic, Maja, Todorovic, Sladjana, Mitrovic, Katarina, Vukovic, Rade, Miljic, Dragana, Savic, Dragan, Milicevic, Mihajlo, Stanimirovic, Aleksandar, Bogosavljevic, Vojislav, Pekic, Sandra, Manojlovic-Gacic, Emilija, Djukic, Aleksandar, Grujicic, Danica, Petakov, Milan
Publicado 2021

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial

por Mistry, Pramod K., Lukina, Elena, Ben Turkia, Hadhami, Shankar, Suma P., Baris, Hagit, Ghosn, Marwan, Mehta, Atul, Packman, Seymour, Pastores, Gregory, Petakov, Milan, Assouline, Sarit, Balwani, Manisha, Danda, Sumita, Hadjiev, Evgueniy, Ortega, Andres, Gaemers, Sebastiaan J. M., Tayag, Regina, Peterschmitt, M. Judith
Publicado 2017

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results

por Mistry, Pramod K., Lukina, Elena, Ben Turkia, Hadhami, Shankar, Suma P., Baris Feldman, Hagit, Ghosn, Marwan, Mehta, Atul, Packman, Seymour, Lau, Heather, Petakov, Milan, Assouline, Sarit, Balwani, Manisha, Danda, Sumita, Hadjiev, Evgueniy, Ortega, Andres, Foster, Meredith C., Gaemers, Sebastiaan J. M., Peterschmitt, M. Judith
Publicado 2021